title: 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
abstract: Haloperidol decanoate is widely used in the maintenance treatment of schizophrenia and other psychotic disorders, but knowledge concerning its pharmacokinetics at the injected region is very limited. Because the chemical structure of haloperidol contains fluorine, in vivo 19F-magnetic resonance (MR) spectroscopy (repetition time (TR) = 1 s) and chemical shift imaging (CSI; TR = 1 s, pixel size = 15 x 15 mm) were performed in schizophrenic patients who were treated with haloperidol decanoate (three men and one woman) to measure its diachronic change at the injection point and visualize its local distribution after intramuscular injection. 19F signals (T1 time = 365 ms) were obtained at the haloperidol decanoate-injected region. The decrease rate of the signal-to-noise ratio (SNR) by 19F-MR spectroscopy seemed large in comparison with that of the plasma haloperidol concentration. The distribution was clearly visualized by 19F-CSI for a few days after the injection, but after 1 week could no longer be seen. Although the slow-release characteristics of depot neuroleptics have been explained by the slow diffusion of esterified neuroleptics from the oil vehicle, this result may suggest that there are other mechanisms involved in maintaining the plasma haloperidol concentration. In vivo 19F-MR spectroscopy and CSI are potentially applicable for the pharmacokinetic analysis of haloperidol and other drugs containing fluorine in their structure.
authors.affiliation: Brain Imaging Project, National Institute of Radiological Sciences, Anagawa, Inage-Ku, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sassa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Suhara
authors.forename: Hiroo
authors.initials: H
authors.lastname: Ikehira
authors.forename: Takayuki
authors.initials: T
authors.lastname: Obata
authors.forename: Franck
authors.initials: F
authors.lastname: Girard
authors.forename: Shuji
authors.initials: S
authors.lastname: Tanada
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Okubo
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D005461:Fluorine; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D006801:Humans; D007273:Injections, Intramuscular; D007554:Isotopes; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D014150:Antipsychotic Agents; D007554:Isotopes; D005461:Fluorine; C033563:haloperidol decanoate; D006220:Haloperidol